ArcoScreen has developed a new cell membrane receptor screening platform based on a microfluidic system and focusing on G Protein Coupled Receptors (GPCRs). This novel and unique patented assay embedded in a microfluidic chip, called SynScreen, is currently the only mean of rapidly and accurately identifying drugs targeting GPCRs directly on primary patient cells. The implications are game-changing: more accurate, cheaper and faster drug discoveries.
“We are very thankful to the Lopez-Loreta foundation and all the jury members who believe in our mission at ArcoScreen. We are currently performing pilot studies with relevant key opinion leaders and have first paying customers in our pipeline. Those significant achievements could not have been possible without our dedicated and talented team,” said Dr. Margaux Duchamp, co-founder and CEO of ArcoScreen who won earlier this year the Musy Prize.
Funding to build on the current momentum
“This financing will help ArcoScreen grow and scale up our product development, taking us to the next step in our business development plan. Our technology has received growing interest from the industry. This funding will be used to continue building on this momentum,” added Dr. Thamani Dahoun, co-founder and CTO of ArcoScreen.
(Press release)
Please login or sign up to comment.
Commenting guidelines